VIRX Insider Trading

Insider Ownership Percentage: 10.69%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $0.00

Viracta Therapeutics Insider Trading History Chart

This chart shows the insider buying and selling history at Viracta Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$50k$0$50kTotal Insider BuyingTotal Insider Selling

Viracta Therapeutics Share Price & Price History

Current Price: $0.03
Price Change: Price Increase of +0.0066 (32.67%)
As of 04/3/2025 04:59 PM ET

This chart shows the closing price history over time for VIRX up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
MayJunJulAugSepOctNovDecJanFebMar$0.03Closing price on 04/03/25:

SEC Filings (Institutional Ownership Changes) for Viracta Therapeutics (NASDAQ:VIRX)

31.37% of Viracta Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at VIRX by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
2022202320242025$0bought$0soldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$20k-$10k$0$10k$20kTotal InflowsTotal Outflows
Viracta Therapeutics logo
Viracta Therapeutics, Inc., a clinical-stage precision oncology company, focuses on the treatment and prevention of virus-associated cancers that impact patients worldwide. Its lead product candidate is Nana-val, an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir. The company's Nana-val is in various ongoing clinical trials, including NAVAL-1, an open-label Phase 2 basket trial for the treatment of multiple subtypes of relapsed/refractory Epstein-Barr virus-positive (EBV+) lymphoma, as well as an open-label Phase 1b/2 trial for the treatment of EBV+ recurrent or metastatic nasopharyngeal carcinoma and other EBV+ solid tumors. Its product pipeline also includes vecabrutinib, a clinical-stage product candidate; and VRx-510, a preclinical product candidate. The company is headquartered in Cardiff, California.
Read More on Viracta Therapeutics

Today's Range

Now: $0.03
Low: $0.02
High: $0.03

50 Day Range

MA: $0.04
Low: $0.01
High: $0.17

52 Week Range

Now: $0.03
Low: $0.01
High: $1.31

Volume

222,755 shs

Average Volume

1,072,115 shs

Market Capitalization

$1.07 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.44

Who are the company insiders with the largest holdings of Viracta Therapeutics?

Viracta Therapeutics' top insider investors include:
  1. Daniel R Chevallard (CFO)
  2. Mark Rothera (CEO)
Learn More about top insider investors at Viracta Therapeutics.